No drugs in an age of plenty: Urging governments to redress the balance

Interdisciplinary Science Reviews

Volumn 31, Issue 1, 2006, Pages 3-8

  Torreele, Els ^a,b  

^a Drugs for Neglected Diseases initiative DNDi   (Switzerland)

^b Drugs for Neglected Diseases Initiative DND I   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SOCIAL SCIENCES;

EID: 33745662617     PISSN: 03080188     EISSN: None     Source Type: Journal    
DOI: 10.1179/030801806X84174     Document Type: Review

References (7)

1. World Health Report 2004; 2005, Geneva, World Health Organization.
2. P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing and N. Ford: 'Drug development for neglected diseases: a deficient market and a public policy failure', Lancet, 2002, 359, 2188-2194 (updating in progress).
3. D. Pécoul, J. Orbinski and E. Torreele (ed.): Fatal Imbalance: The Crisis in Research and Development far Drugs for Neglected Diseases, 18; 2001, Geneva, MSF Access to Essential Medicines Campaign/Drugs for Neglected Diseases Working Group (www.accessmed-msf.org/documents/fatal_imbalance_2001.pdf).
4. See also H. Pécoul: 'New drugs for neglected diseases: from pipeline to patients', PLoS Medicine, 2004, 1, e6.
5. K. Torreele: The Biochemist, 2003, 25, (6), 11-14.
6. M. Moran et al.: The New Landscape of Neglected Disease Drug Development; 2005, London, LSE,/Wellcome Trust (www.wellcomc.ac.uk/assets/wtx026592.pdf).
7. The appeal website is at www.researchappeal.org.